Mahesh Hari Kolhe, Ritu Mehra Gilhotra, Govind Sarangdhar Asane
Mahesh Hari Kolhe1,2*, Ritu Mehra Gilhotra3, Govind Sarangdhar Asane4
1Research Scholar, Gyan Vihar School of Pharmacy, Suresh Gyan Vihar University, Mahal, Jagatpura, Jaipur, Rajasthan, India- 302017.
2Department of Pharmaceutics, Pravara Rural College of Pharmacy, Pravaranagar, Ahmednagar, Maharashtra, India – 413736.
3Principal and Dean, Gyan Vihar School of Pharmacy, Suresh Gyan Vihar University, Mahal, Jagatpura, Jaipur, Rajasthan, India- 302017.
4St. John Institute of Pharmacy and Research, Palghar, Maharashtra, India- 401404.
Volume - 14,
Issue - 4,
Year - 2021
Atenolol is beta blocker absorbed through GIT use for heart diseases. Single tablets, floating tablets and sustained released formulations studied are insufficient to produce effective dose to enhance bioavailability and effectiveness. Our study is focused on development of capsule dosage form containing immediate release (IR) and floating extended release (ER) tablets for monitoring release of atenolol in single dosage form. Two different tablets for IR and ER were prepared in three different combinations (Batch). Pre-formulation and post formulation parameters found to be within acceptable limits of formulation. Release behavior of individual tablets and capsule containing two tablets were studied. Among the batches, capsules containing smaller amount of atenolol in IR and large amount of Atenolol in ER (batch II) showed impressive drug release pattern. This formulation was stable even after a month and achieved optimum release behavior of immediate release and sustained release. This study could be used for effective treatment for different heart complications and reduce toxicity due to high plasma concentration in increased dose frequency.
Cite this article:
Mahesh Hari Kolhe, Ritu Mehra Gilhotra, Govind Sarangdhar Asane. Development of Capsule containing Immediate Release Tablet and Extended Release Floating Tablet for Monitoring Release of Atenolol. Research Journal of Pharmacy and Technology. 2021; 14(4):2216-0. doi: 10.52711/0974-360X.2021.00393
Mahesh Hari Kolhe, Ritu Mehra Gilhotra, Govind Sarangdhar Asane. Development of Capsule containing Immediate Release Tablet and Extended Release Floating Tablet for Monitoring Release of Atenolol. Research Journal of Pharmacy and Technology. 2021; 14(4):2216-0. doi: 10.52711/0974-360X.2021.00393 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-4-69
1. January CT et al. Guideline for the management of patients with atrial fibrillation: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm. 2019; 16(8): e66-e93.
2. Ezekowitz JA et al. Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology. 2017; 33(11): 1342-1433.
3. Rouge N et al. Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. Pharmaceutica Acta Helvetiae. 1998; 73(2): 81-87.
4. Asada T et al. Formulation of a poorly water-soluble drug in sustained-release hollow granules with a high viscosity water-soluble polymer using a fluidized bed rotor granulator. International Journal of Pharmaceutics. 2018; 541(1-2): 246-52.
5. Sahu S et al. Formulation and evaluation of sustain released matrix tablet of atenolol, Journal of Drug Delivery and Therapeutics. 2019; 9(1): 183-189.
6. Gupta S et al. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharmaceutics. 2013; 16: 2013.
7. Havaldar VD, Kulkarni AS, Dias RJ, Aloorkar NH, Mali KK. Floating matrix tablets of atenolol: Formulation and in vitro evaluation. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm. 2014 Aug 25; 3(4).
8. Jannin V, Rodier JD, Musakhanian J. Polyoxylglycerides and glycerides: effects of manufacturing parameters on API stability, excipient functionality and processing. International Journal of Pharmaceutics. 2014;466(1-2): 109-21.
9. Ghebre-Sellassie I. Pellets: a general overview in Pharmaceutical pelletization technology. Drugs and the Pharmaceutical Sciences, Marcel Dekker Inc., New York. 1989; 37.
10. Kim MS, Kim JS, Hwang SJ. The effect of sodium alginate on physical and dissolution properties of Surelease®-matrix pellets prepared by a novel pelletizer. Chemical and Pharmaceutical Bulletin. 2007; 55(11): 1631-4.
11. Rahman Z, Ali M, Khar RK. Design and evaluation of bilayer floating tablets of captopril. Acta Pharmaceutica. 2006 Jan 1;56(1): 49-57.
12. Patil GB et al. Design and development of novel dual-compartment capsule for improved gastroretention. ISRN Pharmaceutics. 2013; 2013.
13. Yang L, Eshraghi J, Fassihi R. A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. Journal of Controlled Release. 1999; 57(3): 215-22.
14. Srivastava AK, Wadhwa S, Ridhurkar D, Mishra B. Oral sustained delivery of atenolol from floating matrix tablets—formulation and in vitro evaluation. Drug Development and Industrial Pharmacy. 2005; 31(4-5): 367-74.
15. Rekhi GS, Nellore RV, Hussain AS, Tillman LG, Malinowski HJ, Augsburger LL. Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets. Journal of Controlled Release. 1999; 59(3): 327-42.
16. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews. 2012 Dec 1; 64: 163-74.
17. Matthews BR. Regulatory aspects of stability testing in Europe. Drug development and industrial pharmacy. 1999;25(7): 831-56.
18. Sankula KR and Rao DN. Formulation and evaluation of gastro retentive floating drug delivery system of Atenolol. The Pharma Innovation Journal. 2014; 3(5): 11-18.
19. Amrutkar PP, Chaudhari PD, Patil SB. Design and in vitro evaluation of multiparticulate floating drug delivery system of zolpidem tartarate. Colloids and Surfaces B: Biointerfaces. 2012; 89: 182-7.